All samples·Sample analysis
Get your own pass — $199
granted.bioAll samples
Analysis

radioligand therapy for prostate cancer

Overview
  • Dashboard
Analysis
  • What Surprised Us
  • Field Maturity
  • Funding Landscape
  • Competitive Topology
  • White Space
  • Market Context
Data
  • Projects115
  • Clinical Trials500
  • Patents29
  • Publications646
  • Organizations52
  • Researchers125
Reference
  • Methodology
Back
radioligand therapy for prostate cancerOrganizationsCASE WESTERN RESERVE UNIVERSITY

CASE WESTERN RESERVE UNIVERSITY

Projects attributed to CASE WESTERN RESERVE UNIVERSITY within this analysis sample.

In This Analysis
Projects
5
NIH Funding
$2.8M
Projects(5)
ProjectPICategoryFunding
Fluorescence image guided surgery, adjuvant PDT, and the immune response
5R01EB034660-02
BASILION, JAMES PETERTherapeutics$1.2M
Highly selective targeted theranostics for prostate cancers
5R01CA255925-04
BASILION, JAMES PETERTherapeutics$635K
PSMA-targeted AuNPs for MR guided radiotherapy and radiosensitization
R01CA260847
AYDOGAN, BULENTTherapeutics$632K
Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate Cancer
5U01CA257638-03
SPRATT, DANIEL EIDELBERGTherapeutics$309K
Ultrasound-triggered nanobubble gene therapy for prostate cancer radiosensitization
F30CA318437
CHEN, LAURATraining$55K
See CASE WESTERN RESERVE UNIVERSITY’s full platform profile
Cross-source view across the entire granted.bio dataset — projects, trials, patents, and publications spanning every topic, not just this analysis.